thiazolyl blue has been researched along with Biliary Tract Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jang, JY; Kim, SW; Ku, JL; Park, JG; Park, YH | 1 |
| Kitajima, Y; Koga, Y; Miyazaki, K; Miyoshi, A; Sato, K | 1 |
2 other study(ies) available for thiazolyl blue and Biliary Tract Cancer
| Article | Year |
|---|---|
Presence of CCK-A, B receptors and effect of gastrin and cholecystokinin on growth of pancreatobiliary cancer cell lines.
Topics: Biliary Tract Neoplasms; Cell Count; Cell Division; Cell Line, Tumor; Cholecystokinin; Gastrins; Hormone Antagonists; Humans; Pancreatic Neoplasms; Receptor, Cholecystokinin A; Receptor, Cholecystokinin B; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Thiazoles | 2005 |
Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Biliary Tract Neoplasms; Cell Line, Tumor; Enzyme Inhibitors; Epigenesis, Genetic; Fluorouracil; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Sequence Data; Protein Synthesis Inhibitors; Tetrazolium Salts; Thiazoles | 2006 |